Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

Change can mean innovation and growth. But change can also mean disruption, high costs, and breakdowns in processes. For healthcare organizations that are looking to not just survive but thrive in the new economy, we took a loo...

View Blog Post
Blog Post

To commemorate World AIDS Day, we interviewed Ross Slotten, MD, a family practitioner specializing in the care of people with HIV/AIDS in Chic...

View Blog Post
White Paper

The new health economy is here. Do you have the right knowledge resources in place? The rapid pace of innovation, the rise of consumerism, an aging population, and movement toward price transparency are placing sign...

View White Paper

Filter by Type

Sign up to receive the latest news and information!

Sign Up